Literature DB >> 15061661

Sexually transmitted herpes simplex viruses.

Maria Karolina Jonsson1, Britta Wahren.   

Abstract

Herpes simplex virus type 2 (HSV-2) is the dominant primary causative agent in genital ulcerative infections. Since infections with HSV-2 usually are acquired through sexual contacts, antibodies are rarely found before the age of onset of sexual activity. Although most genital infections are caused by HSV-2, a rising proportion has become attributable to primary type 1 herpes simplex virus (HSV-1) infection. Genital HSV-1 infections are usually both less severe clinically and less prone to recur. HSV-1 infection might render a certain protection against an HSV-2 infection and seems to mitigate the HSV-2 illness. It is not yet clear whether the advent of HSV-1 genitally will reduce the general occurrence of HSV-2. Increased efforts to protect against sexual transmission of the herpes viruses should have an effect on the transmission of other chronic diseases, such as the human immunodeficiency virus (HIV). In conclusion, it seems that increased sexual promiscuity and more advanced sexual techniques contribute to an unnecessary rise in prevalence of genital HSV infections, thus also affecting transmission of other genitally manifested diseases in targeted populations.

Entities:  

Mesh:

Year:  2004        PMID: 15061661     DOI: 10.1080/00365540310018905

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  8 in total

1.  Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania.

Authors:  Mabula Joseph Kasubi; Arvid Nilsen; Howard S Marsden; Tomas Bergström; Nina Langeland; Lars Haarr
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.

Authors:  William P Halford; Ringo Püschel; Edward Gershburg; Andrew Wilber; Svetlana Gershburg; Brandon Rakowski
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

3.  Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine.

Authors:  William P Halford; Ringo Püschel; Brandon Rakowski
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

4.  Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects.

Authors:  David M Koelle; Amalia Magaret; Christopher L McClurkan; Michael L Remington; Terri Warren; Florentina Teofilovici; Anna Wald
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

Review 5.  Management of neonatal herpes simplex virus infections.

Authors:  Bishara J Freij
Journal:  Indian J Pediatr       Date:  2004-10       Impact factor: 5.319

6.  Effects of thyroid hormone on HSV-1 gene regulation: implications in the control of viral latency and reactivation.

Authors:  Shao-Chung Hsia; Gautam R Bedadala; Matthew D Balish
Journal:  Cell Biosci       Date:  2011-07-14       Impact factor: 7.133

7.  Prevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicide.

Authors:  Jianmin Chen; Sanat K Davé; Anthony Simmons
Journal:  Virol J       Date:  2004-11-23       Impact factor: 4.099

8.  The Peptide A-3302-B Isolated from a Marine Bacterium Micromonospora sp. Inhibits HSV-2 Infection by Preventing the Viral Egress from Host Cells.

Authors:  Sanya Sureram; Irene Arduino; Reiko Ueoka; Massimo Rittà; Rachele Francese; Rattanaporn Srivibool; Dhanushka Darshana; Jörn Piel; Somsak Ruchirawat; Luisa Muratori; David Lembo; Prasat Kittakoop; Manuela Donalisio
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.